PDCD1 and non-small cell lung carcinoma: In addition, with the advent of immune-based therapy namely, programmed cell death protein 1 and programmed death ligand 1 (PD-1 and PD-L1, respectively) inhibitors, improvements in NSCLC treatment outcomes are tremendous.